Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab

Lynch syndrome is caused by mutations in mismatch repair genes that lead to microsatellite instability (MSI). An increased number of mutation-associated neoantigens have been observed in patients with high-frequency MSI (MSI-H) cancer; in addition, membranous programmed death ligand-1 (PD-L1) tends...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawashima, Yosuke, Nishikawa, Shingo, Ninomiya, Hironori, Yoshida, Reiko, Takano, Natsuki, Oguri, Tomoyo, Kitazono, Satoru, Yanagitani, Noriko, Horiike, Atsushi, Ohyanagi, Fumiyoshi, Ishikawa, Yuichi, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548921/
https://www.ncbi.nlm.nih.gov/pubmed/31092773
http://dx.doi.org/10.2169/internalmedicine.1673-18
Descripción
Sumario:Lynch syndrome is caused by mutations in mismatch repair genes that lead to microsatellite instability (MSI). An increased number of mutation-associated neoantigens have been observed in patients with high-frequency MSI (MSI-H) cancer; in addition, membranous programmed death ligand-1 (PD-L1) tends to be expressed at higher levels in MSI-H cancers than in microsatellite-stable cancers. MSI-H cancer patients are therefore considered to be susceptible to immune checkpoint blockade. We herein report for the first time a case of lung adenocarcinoma with Lynch syndrome and the response to nivolumab.

Ejemplares similares